Bet on Winning DuPont Analysis & Pick 4 Top Stocks

The article promotes DuPont analysis to explain changes in ROE using profit margin, asset turnover, and the equity multiplier, and suggests a screen to find “winning” stocks. Four highlighted names—Casey’s (CASY) with 15.83% average earnings surprise, EMCOR (EME) with 32.26%, EverQuote (EVER) with 149.58%, and Sprouts (SFM) with 15.29%—pass criteria including profit margin ≥3, asset turnover ≥2, and equity multiplier between 1–3 (plus Zacks Rank ≤2 and price >$5). Overall, it’s a methodological/stock-screening piece with limited immediate information likely to move markets.

Analysis

This is less a catalyst than a factor confirmation event. Screens like this tend to reinforce existing “quality” ownership rather than create fresh alpha, so the immediate market effect is usually modest unless one of the names is already crowded or expensive. The actionable edge is in what the screen implies about balance-sheet discipline: businesses that generate ROE through turnover and margin rather than leverage should hold up better if funding costs stay elevated and growth slows.

The main second-order winner is not just the named companies, but the broad quality sleeve: profitable, capital-light operators should attract incremental allocators looking to de-risk from levered cyclicals. That argues for relative strength in consumer-discretionary names with operating leverage but low capex needs, and for industrial/service names where backlog conversion is still intact. The counterpoint is that “high ROE” is often a late-cycle crowding factor; when everyone pays up for clean financials, forward returns get pulled forward and the multiple can do the damage even if fundamentals stay fine.

Among the names, EVER is the most fragile because marketplace economics can look excellent on a trailing basis while underwriting/lead-cost pressure shows up later; it is the easiest to disappoint if insurance pricing normalizes. SFM and CASY are more durable defensively, but both can be good businesses at bad prices, so the risk is multiple compression rather than earnings collapse. EME has the clearest medium-term fundamental support if infrastructure/data-center spend stays strong, making it the best quality-versus-cyclical expression here.

The contrarian view is that the screen is backward-looking and may already be reflected in prices; the real question is whether next-quarter revisions can outpace the market’s quality premium. If rates fall or credit loosens, lower-quality/high-leverage names could outperform on multiple expansion, reversing the relative trade even if these companies keep executing.

Key Decisions for Investors

• Prefer EME as the cleanest long within the list on a 3-6 month horizon; use pullbacks after earnings/sector weakness rather than chasing the screen, with a stop if backlog growth or margin conversion rolls over.
• Fade EVER on strength versus the quality basket if insurance lead costs or conversion metrics soften; best expression is a relative short against a broader quality ETF/peer basket over 1-3 months.
• Hold CASY and SFM as defensive compounders, but only at disciplined entries; the risk/reward is skewed to multiple compression if same-store-sales decelerate, so size smaller than an earnings-driven long.
• Pair trade: long QUAL or USMV vs short a high-leverage cyclicals basket over the next 1-3 months if rates remain sticky; this is a cleaner expression of the article’s signal than single-name longs.
• Set alerts on forward EPS revisions and valuation: if any of CASY/SFM/EME re-rate materially above their growth trajectory, take profits rather than assuming the screen remains supportive.